FTC Pulls Amgen-Horizon Merger Case, Citing Possible Deal
The Federal Trade Commission appears to be mulling a deal resolving its challenge to Amgen's planned $27.8 billion purchase of Horizon Therapeutics, publicly disclosing that the agency had pulled the case...To view the full article, register now.
Already a subscriber? Click here to view full article